

The Marine Biodiscovery Pipeline

Marcel Jaspars Marine Biodiscovery Centre University of Aberdeen Scotland, UK m.jaspars@abdn.ac.uk

Professor Marcel Jaspars

- Professor of Organic Chemistry, University of Aberdeen
- Director of Marine Biodiscovery Centre, University of Aberdeen
- Project Leader, PharmaSea EU FP7 Consortium
- Co-Author of ESF Marine Board Position Paper "Marine Biotechnology – A New Vision and Strategy for Europe"
- Visiting Professor and Scientific advisor at University of Tromsø
- Member of the governing board of the Industrial Biotechnology Innovation Centre



Offers advantage over comparable terrestrial resource: Superior performance Better economics

Unprecedented activity in particular application: Enzymes: new reactivity/new biotransformation Small molecules: new mechanism of action Materials: new properties



The Marine Biodiscovery Process

IBiodiscovery is the discovery of compounds and associated ideas from natural sources to develop novel biomedicines.

IBiodiscovery generates chemical diversity that is used to find initial biological activity in disease focused screens

IBiodiscovery also includes the development of biomedical research tools, antifoulants, catalysts, nutraceuticals and cosmeceuticals.





PharmaSea:

Increasing Value and Flow in the Marine Biodiscovery Pipeline



Why Marine?

Diversity of Habitat



Jørgensen Nat Rev Microbiology, 2007, 5, 770



Extreme Marine Environments



55T Climitology for January

Cold Oceans

Deep Oceans 95 % > 1000 m deep 50 % > 3000 m deep Average depth = 3790 m 1-3% trench ecosystems



Thermal Vents



Marine Animal Biodiversity



Marine Microbial Diversity





Taxonomic 'space'

Marine and terrestrial species clearly separated.



Biological Diversity = Chemical Diversity



Small Molecules

Biomolecules



Marine and Terrestrial Chemical Diversity are Different



FIGURE 1

Power-law behavior of novel scaffolds in marine agent space. The number of scaffolds (*N*) decays with the increase of their occurrence in agent space (*S*) and follows the equation $N = aS^{-b}$.

Kong, Drug Discovery Today, 2010, 15, 884

- 71% of scaffolds are exclusively marine
- These cover only 30% of marine natural products
- Many marine natural products scaffolds appear only once



Marine Natural Products on the Market



Vent Polymerase Origin: Vent bacterium Production: Recombinant



Prialt for pain Origin: Phillippino cone snail Production: Recombinant



ω-3 polyunsaturated fatty acidsfor heart disease Origin: FishProduction: Fish



Halaven for cancer Origin: Japanese deep water sponge Production: Chemical synthesis PHARMASEA

The Marine Biodiscovery Process





Little Sampling Done Beyond 3000 m





Current Cruise Protocols Very Heterogeneous



No requirement for post cruise data (eg genetic data) to be deposited Species may not be identified until later, if at all PHARMASEA

Cruise Application



Table 1. Proposed sampling coordinates at each site (by nominal depth)						
Nominal Depth (m)	Latitude	Longitude	Distance to next station			
			(nm)			
5200	61° 0304S	58° 6927W	3.5			
5100	61° 0640S	58° 6481W	2.0			
5000	61° 0806S	58° 6246W	2.1			
4000	61° 1393S	58° 5316W	7.8			
3000	61° 2420S	58° 3869W	6.2			
2000	61° 3482S	58° 2949W	36*			

Note: * = *distance to King George Island*

Table 2. Work Programme showing details of 24 stations	s spanning 6 sampling depths
--	------------------------------

Station #	Nominal Depth (m)	Gear	Time ¹ (h) [+turnaround time ²]	Total time per event (h)	Total time per depth (h)
Arrive ³	-	-	-	4	ŀ
1	5200	Multi-core	3.5 [+1]	4.5	
2	5200	Multi-core	3.5 [+2]	5.5	
3	5200	Box core	3.5	3.5	
5	5200	Piston core	3.5 [+2]	5.5	
5	5200	Piston core	3.5 [+2]	5.5	28.5



Research Vessels



RRS Discovery (UK)

- High daily rate
- Limited number of vessels globally
- Access competitive
- Long time between bid for time and actual cruise
- Many different types of science accommodated may lead to compromises
- Shared resources and bartering systems operate to optimise usage



Chikyu (Japan)

PHARMASI

Alternatives for Collection in ABNJ

Charter Vessels

Rapid access Lower cost Dedicated to one task No requirement to deposit data

Foundation Vessels

Different requirements, eg image copyright, open access data etc

Survey Vessels

Baseline surveys for companies often carried out by 'neutral' academic institutions Data can be used for publication with agreement No requirement to deposit data Cruise path may be commercially sensitive



INTO THE ABYSS

The world's fleet of deep-sea submersibles has dwindled further with the loss of Nereus.

submersible 🏻 📥 Uncrewed

(not to scale)	
Depth (m)	-
Little sunlight Deepest scuba dive	(FIII
-1.000 No sunlight	
Estimated depth of Deepwater Horizon oil-well leak	
-2.000	
Maximum dive by mammal -3,000 — Cuvier's beaked whale	~
Titanic wreck	
	ź
-5.000	
SENTRY USA	_
-8,000	
Puerto Rico Trench. Deepest point in the Atlantic Ocean	
-9.000	
- 10,000	
Mariana Trench, Deepest point in the Pacific Ocean	Ł
t DEEPSEA CHALLENGER USA	

Lost at sea 2003 NEREUS USA Lost at sea 2014 TRIESTE Italy Retired

Submersibles



ROV Isis (UK) (6500 m)



ROV Nereus (US) (11000 m)



Shinkai (Japan) (6500 m)



Deepsea challenger (US) (11000 m) PHARMASEA

Data Logging for Research Cruises





Sampling Devices







The Marine Biodiscovery Process





Sample Data and Storage

Metadata may include

ILocation IDepth ITemperature ISalinity IpH IOxygen content ISeafloor conditions

Sample storage IAmbient temperature ICooler (4°C) IFreezer (-20°C) I-80°C Freezer ILiquid nitrogen (-196°C) IFormaldehyde IEthanol IDNA/RNA preservation liquids



Are Current Repositories Sufficient?

Further sampling is essential for the following reasons:

- Origin may be difficult to ascertain (eg location, depth, collector, date, ownership etc). A minimal data set is imperative.
- IP status not clear
- May not have been collected in a way consistent with proposed use
- May not have been stored correctly to ensure sufficient quality for proposed use.
- The amount of material may not be sufficient for proposed multiple uses.
- Very few locations have been sampled so repository may not be representative of ABNJs.



If previous points can be addressed then such a repository might be viable

- The rules for terrestrial biorepositories may not apply for their marine equivalent.
- Much information on biorepositories is based on situation with respect to plants where samples can be propagated.
- A deepsea core sample or a marine macroorganism collected on one sampling expedition is finite.
- Microbes can be cultured but again culturing a microbe from a hydrothermal vent is quite different from culturing a microbe from a terrestrial habitat.



The Marine Biodiscovery Process





Biomass









The Marine Biodiscovery Process





Extraction and Purification





Solvent-solvent partition

Size-exclusion chromatography



High performance Liquid chromatography



The Marine Biodiscovery Process





Assay





Cell based



Enzyme based



The Marine Biodiscovery Process





Structure Determination



Metagenomic Approach



Bioinformatic Databases and the Metagenomic Approach

- Who acquired/deposited the data and with what authority?
- Who has access to the data?
- Is genome and metagenome information sufficient?
- Many genes found in marine species are not in the current bioinformatic databases
- The function of many of these genes cannot be determined without laboratory work
- Difficulty in cloning genes of marine origin
- Lack of suitable tools (vectors/hosts)



Gene Synthesis

GATTACAGGACGCTT ATTTTTCGACGATGC TTGGGGAAATGCAAA GATTCAGCTAAAGTC

Gene sequence





Molecule



Conclusions

- The marine environment clearly provides an exciting source of new bioactive compounds
- The marine environment and its biodiversity is largely unexplored compared to the terrestrial environment and so cruises and sampling will continue and are necessary for both basic and applied research purposes
- A greater degree of coordination of relevant activities within the scientific community is necessary at a global level
- Capacity building is required to support these efforts







"The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013 under grant agreement n° 312184)"